Techniques for Modelling and Optimizing Dialysis Toxin Displacer Compounds

ChangeBridge: Patent Grants - Medical Devices (A61M)

Published April 7th, 2026

Detected April 7th, 2026

Summary

USPTO granted Fresenius Medical Care Holdings, Inc. Patent US12597482B2 covering systems and methods for modeling and optimizing dialysis toxin displacer compounds using quantitative structure-activity relationship (QSAR) models. The patent includes 20 allowed claims for techniques predicting compound binding affinity to protein binding sites in dialysis processes. The invention relates to A61M medical device classifications and computational biology applications.

View original document View source feed page

What changed

USPTO issued Patent US12597482B2 to Fresenius Medical Care Holdings, Inc. for novel systems and methods involving dialysis toxin displacer compound optimization. The patent covers constructing QSAR models for multiple binding sites, analyzing candidate compounds for binding affinity, and selecting displacer compounds for dialysis procedures. The invention encompasses computational methods (G16B, G16C, G16H classifications) integrated with medical device technology (A61M).\n\nCompetitors developing dialysis equipment, displacer compounds, or computational modeling tools for renal therapy should review this patent for freedom-to-operate implications. The patent may affect research and development in dialysis optimization, protein binding analysis, and therapeutic compound selection. Medical device manufacturers and pharmaceutical companies in the renal care space should consider this IP position when planning product development strategies.

What to do next

Monitor for updates

Source document (simplified)

← USPTO Patent Grants

Techniques for modelling and optimizing dialysis toxin displacer compounds

Grant US12597482B2 Kind: B2 Apr 07, 2026

Assignee

Fresenius Medical Care Holdings, Inc.

Inventors

Xia Tao, Vaibhav Maheshwari, Peter Kotanko, Stephan Thijssen, Nadja Grobe

Abstract

Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. In one embodiment, a method for determining a displacer compound may include constructing a plurality of target protein quantitative structure-activity relationship (QSAR) models, one for each of the plurality of binding sites, analyzing a set of candidate compounds using the plurality of QSAR models to determine a set of at least one potential compound with an affinity for binding to each of the plurality of binding sites, and selecting at least one displacer compound from the set of at least one potential compound. Other embodiments are described.